Evaluation of anti-cancer stem cell activity of the anti-DLL4 antibody MEDI0639 in a phase I clinical trial of SCLC.
2016 ◽
Vol 34
(15_suppl)
◽
pp. e20093-e20093
◽
Keyword(s):
Phase I
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2011 ◽
Vol 52
(6)
◽
pp. 1085-1097
◽
Keyword(s):